Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce•
Hisse Senedi Orta Önem
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.14 per share a year ago.
İlgili Semboller 1
TVTX TVTX
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Yorum Yap
Yorumlar
0
Henüz yorum yok
Bu habere ilk yorum yapan kişi olun.